Neurocrine Biosciences (NBIX) Long-Term Debt Repayments (2020 - 2022)

Neurocrine Biosciences (NBIX) reported Long-Term Debt Repayments of $279.0 million for Q2 2022, up 278900.0% quarter-over-quarter from $100000.0 in Q1 2021.

Neurocrine Biosciences (NBIX) Long-Term Debt Repayments (2020 - 2022) Analysis & Trends

Neurocrine Biosciences has reported Long-Term Debt Repayments for 3 years, with the latest figure at $279.0 million in Q2 2022.

  • For the quarter ending Q2 2022, Long-Term Debt Repayments changed N/A year-over-year to $279.0 million; the trailing twelve-month figure through Sep 2023 stood at $279.0 million (changed 0.0% YoY), and the FY2024 full-year result was $308.8 million, changed N/A from the prior year.
  • Long-Term Debt Repayments for Q2 2022 stood at $279.0 million, up from $100000.0 in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $279.0 million in Q2 2022, with the low at $100000.0 in Q1 2021.
  • Historically, Long-Term Debt Repayments has averaged $155.3 million across 3 years, with a median of $186.9 million in 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 23.00 Mn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn -
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn -
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn -
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn -
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn -
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 216,000.00
10 Liquidia 5.64 Bn 5.42 Bn 121.79 Mn 19.97 Mn

Historic Data

Download Data
DateValue
Jun 30, 2022 279.00 Mn
Jun 30, 2022 279.00 Mn
Mar 31, 2021 100,000.00
Mar 31, 2021 100,000.00
Dec 31, 2020 186.90 Mn
Dec 31, 2020 186.90 Mn